NewsBenzingaSystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 Benzinga 2026.10.23 11:36 (GMT+0) Open on Benzinga Other news CEX Platforms See Net Inflows of Over 46,900 BTC in Past 7 Days, Binance Accounts for Over 37,000 PJT Partners Stock: Credit Crisis In AI Is A Golden Opportunity (NYSE:PJT) Arthur Hayes: Has Sold Off All ETH, ENA, UNI and Other Tokens, Plans to Stay on the Sidelines for Now Mark Cuban Says AI Agents Can Be Like ‘Cockroaches’ That Find Ways Into Systems, But Defenders Can Fight Back With AI: ‘We’ve Always Had Hacks’ Nucor Has What It Takes To Capitalize On The Tailwinds In The Steel Market. (NYSE:NUE) Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
Arthur Hayes: Has Sold Off All ETH, ENA, UNI and Other Tokens, Plans to Stay on the Sidelines for Now
Mark Cuban Says AI Agents Can Be Like ‘Cockroaches’ That Find Ways Into Systems, But Defenders Can Fight Back With AI: ‘We’ve Always Had Hacks’
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
